Testing ST-1898 for advanced acral melanoma
Part of Cancer, Skin clinical trials.
This study tests a new oral drug called ST-1898 for people with advanced acral melanoma that has not responded to standard treatments. It aims to see if the drug can shrink or slow the growth of the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and your doctor expects you to live at least 3 more months.
- You have a type of melanoma called acral melanoma (on palms, soles, or under nails) that has spread or cannot be removed and got worse after other treatments.
- You are in good enough health to do daily activities (ECOG score 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your blood cell counts, kidney, and liver function are within a safe range, as checked by your doctor.
- You are willing to provide a tissue sample from a past biopsy or have a new biopsy taken.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two experimental drugs, AK104 or AK112, combined with a targeted therapy called axitinib for people with metastatic mucosal melanoma (a rare type of skin cancer that has spread). The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
This Phase 3 trial tests camrelizumab (an immune-boosting medicine) combined with apatinib (a targeted pill) and temozolomide (chemotherapy) as first treatment for advanced acral melanoma. It may help shrink the cancer and improve outcomes compared with other standard first-line options.
This trial tests a new drug called PRJ1-3024 for people with advanced melanoma that has not responded to standard treatment. The goal is to see if the drug can shrink tumors or slow the cancer's growth.
This trial tests an experimental drug called ST-1898 for people with advanced thyroid cancer that has stopped responding to radioactive iodine treatment and has progressed after at least one targeted therapy. It aims to see if ST-1898 can shrink tumors or slow the disease.
This Phase 2 trial tests three medicines given before surgery for people with high-risk acral melanoma (a skin cancer type). It aims to shrink or control the cancer earlier and see how well the treatment works and is tolerated.
This study tests an experimental drug AMT-253 in people with advanced solid tumors (like melanoma) that have progressed despite prior treatment. The goal is to see if the drug can help shrink or slow the cancer.
Hear when a new Unresectable or Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.